Related Experiment Video
Updated: Mar 21, 2026
Method for Identifying Small Molecule Inhibitors of the Protein-protein Interaction Between HCN1 and TRIP8b
Published on: November 11, 2016
[Identification and verification of the candidate proteins that interact and collaborate with ATF3 in inhibiting
1Department of Pathology, Institute of Oncology, Fujian Medical University, Fuzhou 350001, China.
Objective:
To identify and verify proteins that interact and collaborate with ATF3 in inhibiting hepatocarcinogenesis.
Methods:
Immunoprecipitation (IP), co-IP and protein spectrum analysis were used to identify the protein which interacted with ATF3 in HepG2. Immunohistochemistry (IHC) and Western blot (WB) were used to detect the expression pattern of ATF3 and its candidate interacting proteins in liver tissue.
Results:
The protein expression differences were detected by IP in two HepG2 groups. The experimental group was infected by lentiviral vector with ATF3 over-expression and the control group was infected by mock-vehicle. Several protein bands with expression diversity were analyzed by protein spectrum, which revealed several candidate proteins that may be related with ATF3. Peptide sequences were analyzed by Mascot software and NCBI database. Combined with the existing literature and our study results, Gelsolin (GSN) was identified as a protein closely interacting with ATF3 and confirmed by co-IP, IHC and WB.
Conclusions:
GSN is identified and verified as an interacting protein with ATF3. ATF3 may function as a suppressor of liver cancer via protein-protein interactions with Gelsolin.
Insights
Researchers identified Gelsolin (GSN) as a protein interacting with ATF3, a key factor in suppressing liver cancer. This protein-protein interaction highlights a potential mechanism for ATF3
Area of Science:
- Molecular Biology
- Oncology
- Biochemistry
Background:
- Hepatocellular carcinoma (HCC) remains a significant global health challenge.
- Activating Transcription Factor 3 (ATF3) has shown potential as a tumor suppressor in liver cancer.
- Understanding ATF3's molecular interactions is crucial for developing targeted therapies.
Purpose of the Study:
- To identify and validate protein interactors of ATF3 involved in hepatocarcinogenesis inhibition.
- To elucidate the molecular mechanisms underlying ATF3's tumor-suppressive function in the liver.
Main Methods:
- Utilized immunoprecipitation (IP) and co-immunoprecipitation (co-IP) to detect protein interactions with ATF3 in HepG2 cells.
- Employed protein spectrum analysis (mass spectrometry) to identify candidate interacting proteins.
- Validated protein expression and interaction using Western blot (WB) and immunohistochemistry (IHC) in liver tissue.
Main Results:
- Overexpression of ATF3 in HepG2 cells revealed distinct protein expression profiles.
- Protein spectrum analysis identified several candidate proteins interacting with ATF3.
- Gelsolin (GSN) was confirmed as a direct interacting protein with ATF3 through co-IP, IHC, and WB.
Conclusions:
- Gelsolin (GSN) is identified and validated as a novel interacting protein partner of ATF3.
- ATF3 likely exerts its tumor-suppressive effects in liver cancer through protein-protein interactions with GSN.
- This discovery provides new insights into the molecular pathways of hepatocarcinogenesis and potential therapeutic targets.
